future is now


Goldfarma was founded in 2005 and began as a company engaged in the distribution of solutions in the fields of environment and welfare. It covered an Industrial Division, making use of antimicrobial products and water treatment. However, with the growth of the Pharmaceuticals Division, the Industrial Division was disbanded. Goldfarma positioned itself at the forefront of the market for generic drugs and innovative products in health.

In 2008 we launched the 1st generic of Buprenorphine in Portugal, Buprenorphine Goldfarma. Thus we pioneered to bring added value to this market segment (opiate substitution therapy), offering a cheaper alternative to the benchmark treatment.
In 2010, through international partnerships, Goldfarma entered a new innovation challenge: the marketing of molecular biology and biomedicine products, including genetic testing and testing of food intolerances in the service of Preventive and Predictive Medicine.

Also in 2010, Marketing Authorizations were granted for the marketing of generic drugs Donepezil Goldfarma, Topiramate Goldfarma, consolidating the presence of Goldfarma within the neurosciences. In 2011 we received the Marketing authorization for Escitalopram Goldfarma.

Since 2010 we have expanded our range of OTC products, including food supplements, as Altaflora electrolytes and Optik, and medical devices as KeratoStill and ClipAir
In 2012, we positioned Goldfarma internationally, through the development of a Export Unit for the CPLP market (Community of Portuguese Language Countries), starring globalization of markets as strategic vector for sustained growth.

2013 culminated with the inauguration of Goldfarma Sao Tome and Principe and Mozambique Goldfarma.

In 2013 we launched the hydrogel Flamozil for wounds and burns, the rapid test Xeliac for the screening of celiac disease and NaviVision line for ophthalmology.

In 2014 we launched a new medical device for ophthalmology - Oftalvit (Sodium Hyaluronate 0.2%). We have also launched Magnevit, a food supplement with magnesium and complex B vitamins.

We expanded our portfolio of prescription drugs with the following active substances: ciprofloxacin, paracetamol, simvastatin and fluconazole.

In 2015 we got a marketing authorization for three new strengths of buprenorphine: 1 mg, 4 mg and 6 mg in order to comply with the therapeutic needs of the patients.

We launched one food supplement for ophthalmology – Optik Plus.

Goldfarma celebrates his 10th anniversary. 

We firmly believe that we can respond more satisfactorily to the expectations of society if we continue to provide innovative therapeutic solutions with a sense of ethics and responsibility.

Contact us

  Av. Professor Doutor Augusto Abreu Lopes nº 53 B Lj A
2675-301 Odivelas, Portugal
  + 351 219 346 450
  + 351 219 346 459

Click here to send us comments or suggestions.

Follow us

Facebook icon
LinkedIn icon

Subscribe our news

made by 3gntw Goldfarma © 2013 | All rights reserved Back to top